4 Mar 2015 10:45
Notice of Results
LONDON, ENGLAND, 4 March, 2015 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug development company, expects to announce its annual financial results for the year ended 31 December 2014 on Tuesday 24 March 2015. The results presentation and a webcast recording of the event will be available on the Company's website at www.skyepharma.com.
- Ends -
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 (0)20 7881 0524 |
Jonathan Birt, Investor and Media Relations
| +44 (0)7860 361746 |
N+1 Singer | |
Shaun Dobson/Gillian Martin/Jen Boorer | +44 (0)20 7496 3000 |
FTI Consulting | |
Julia Phillips/Rob Winder/Natalie Garland-Collins | +44 (0)20 3727 1000 |
About Skyepharma PLC
Skyepharma combines proven scientific expertise with validated proprietary technologies to develop innovative oral and inhalation pharmaceutical products. The Group's licenses cover 16 approved inhalation, oral, topical and injectable products, which generate milestones, recurring royalties, and in some cases, product supply revenues. The Group also earns milestones and contract development revenues from new product developments. Products developed by Skyepharma are marketed by some of the world's most respected pharmaceutical companies. For more information, visit www.skyepharma.com